EM-9017
EM-9017 is a novel pharmaceutical compound currently under investigation for its potential therapeutic applications in the treatment of chronic pain and neuropathic disorders. This article provides a comprehensive overview of EM-9017, including its chemical properties, mechanism of action, clinical trials, and potential side effects.
Chemical Properties[edit | edit source]
EM-9017 is a synthetic compound with a complex molecular structure. It is classified as a small molecule drug, designed to interact with specific receptors in the central nervous system. The chemical formula of EM-9017 is C20H25N3O3, and it has a molecular weight of 355.44 g/mol.
Mechanism of Action[edit | edit source]
EM-9017 functions primarily as a selective agonist for the GABAB receptor, a type of G-protein coupled receptor that plays a crucial role in modulating neurotransmission in the brain. By activating these receptors, EM-9017 enhances inhibitory neurotransmission, which can lead to a reduction in neuronal excitability and a decrease in the perception of pain.
Clinical Trials[edit | edit source]
EM-9017 is currently undergoing Phase II clinical trials to evaluate its efficacy and safety in patients with chronic pain conditions, such as fibromyalgia and diabetic neuropathy. Preliminary results have shown promise, with many participants reporting significant pain relief and improved quality of life.
Potential Side Effects[edit | edit source]
As with any pharmacological agent, EM-9017 may cause side effects. Commonly reported adverse effects include dizziness, fatigue, and nausea. More serious side effects, although rare, may include respiratory depression and hypotension. Ongoing studies aim to further elucidate the safety profile of EM-9017.
Regulatory Status[edit | edit source]
EM-9017 has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The drug is currently available only for research purposes and is not yet marketed for clinical use.
Also see[edit | edit source]
Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
